239 related articles for article (PubMed ID: 32981375)
1. Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis.
Monteagudo-Martínez N; Solís-García Del Pozo J; Nava E; Ikuta I; Galindo M; Jordán J
Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1477-1489. PubMed ID: 32981375
[TBL] [Abstract][Full Text] [Related]
2. Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections.
Sivori F; Cavallo I; Kovacs D; Guembe M; Sperduti I; Truglio M; Pasqua M; Prignano G; Mastrofrancesco A; Toma L; Pimpinelli F; Morrone A; Ensoli F; Di Domenico EG
Microbiol Spectr; 2022 Apr; 10(2):e0035122. PubMed ID: 35416701
[TBL] [Abstract][Full Text] [Related]
3. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
4. Linezolid versus vancomycin for skin and soft tissue infections.
Yue J; Dong BR; Yang M; Chen X; Wu T; Liu GJ
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD008056. PubMed ID: 26758498
[TBL] [Abstract][Full Text] [Related]
5. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial.
Li JZ; Willke RJ; Rittenhouse BE; Rybak MJ
Surg Infect (Larchmt); 2003; 4(1):57-70. PubMed ID: 12744768
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model.
Jabés D; Candiani G; Romanó G; Brunati C; Riva S; Cavaleri M
Antimicrob Agents Chemother; 2004 Apr; 48(4):1118-23. PubMed ID: 15047510
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.
McCool R; Gould IM; Eales J; Barata T; Arber M; Fleetwood K; Glanville J; Kauf TL
BMC Infect Dis; 2017 Jan; 17(1):39. PubMed ID: 28061827
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
[TBL] [Abstract][Full Text] [Related]
9. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus.
Werth BJ; Ashford NK; Penewit K; Waalkes A; Holmes EA; Ross DH; Shen T; Hines KM; Salipante SJ; Xu L
Clin Microbiol Infect; 2021 Jun; 27(6):910.e1-910.e8. PubMed ID: 32866650
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis.
Jame W; Basgut B; Abdi A
PLoS One; 2021; 16(11):e0260539. PubMed ID: 34843561
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Esposito S; Noviello S; Leone S
Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080
[TBL] [Abstract][Full Text] [Related]
12. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
[TBL] [Abstract][Full Text] [Related]
13. Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA.
Riccobono E; Giani T; Baldi G; Arcangeli S; Antonelli A; Tellone V; Del Vecchio A; De Joannon AC; Rossolini GM
Int J Antimicrob Agents; 2022 Feb; 59(2):106503. PubMed ID: 34929289
[TBL] [Abstract][Full Text] [Related]
14. Linezolid versus vancomycin for skin and soft tissue infections.
Yue J; Dong BR; Yang M; Chen X; Wu T; Liu GJ
Cochrane Database Syst Rev; 2013 Jul; (7):CD008056. PubMed ID: 23846850
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
Bounthavong M; Hsu DI
Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
[TBL] [Abstract][Full Text] [Related]
16.
Guzek A; Rybicki Z; Tomaszewski D
Indian J Med Microbiol; 2018; 36(1):119-120. PubMed ID: 29735840
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant
Maraki S; Mavromanolaki VE; Stafylaki D; Iliaki-Giannakoudaki E; Hamilos G
Antibiotics (Basel); 2023 May; 12(5):. PubMed ID: 37237803
[TBL] [Abstract][Full Text] [Related]
18. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
Soriano A; Rossolini GM; Pea F
Expert Rev Anti Infect Ther; 2020 May; 18(5):415-422. PubMed ID: 32223465
[No Abstract] [Full Text] [Related]
19. Linezolid vs. vancomycin in treatment of methicillin-resistant staphylococcus aureus infections: a meta-analysis.
Li J; Zhao QH; Huang KC; Li ZQ; Zhang LY; Qin DY; Pan F; Huang WX
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3974-3979. PubMed ID: 28975963
[TBL] [Abstract][Full Text] [Related]
20. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
Stein GE; Wells EM
Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
